Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Johnson & Johnson (JNJ)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 377,585,088
  • Shares Outstanding, K 2,684,000
  • Annual Sales, $ 71,890 M
  • Annual Income, $ 16,540 M
  • 36-Month Beta 0.78
  • Price/Sales 5.26
  • Price/Cash Flow 17.01
  • Price/Book 5.27

Price Performance

See More
Period Period Low Period High Performance
1-Month
129.05 +9.90%
on 09/29/17
142.98 -0.80%
on 10/19/17
+6.61 (+4.89%)
since 09/19/17
3-Month
129.05 +9.90%
on 09/29/17
142.98 -0.80%
on 10/19/17
+6.62 (+4.90%)
since 07/19/17
52-Week
109.32 +29.74%
on 12/07/16
142.98 -0.80%
on 10/19/17
+27.24 (+23.77%)
since 10/19/16

Most Recent Stories

More News
Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.

XLV : 83.66 (+0.46%)
VHT : 155.36 (+0.35%)
JNJ : 141.73 (+0.75%)
IYH : 175.92 (+0.46%)
PFE : 36.32 (+1.37%)
UNH : 204.30 (-0.45%)
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?

Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.

JNJ : 141.73 (+0.75%)
LLY : 86.15 (+0.49%)
IMGN : 6.24 (-2.80%)
NVS : 86.02 (-0.02%)
Varian Medical (VAR) Initiates Halcyon Treatment in Europe

Varian (VAR) has been taking initiatives to gain customers for its broad spectrum of products, especially targeting emerging markets.

ABT : 55.98 (+0.38%)
VAR : 105.46 (+1.02%)
JNJ : 141.73 (+0.75%)
TMO : 191.43 (+1.17%)
Global Demand for Electrophysiology and Medical Devices Flourishing With Opportunities in Healthcare Sector

PALM BEACH, Florida, October 19, 2017 /PRNewswire/ --

ABT : 55.98 (+0.38%)
BSX : 29.45 (-0.24%)
JNJ : 141.73 (+0.75%)
MRK : 63.89 (+0.60%)
BSGM : 1.5900 (+9.72%)
Global Demand for Electrophysiology and Medical Devices Flourishing With Opportunities in Healthcare Sector

The medical device sector continues to expand and grow as a result of physicians making the formative decision whether you need medicine or a medical device such as a pacemaker, an implantable cardioverter...

ABT : 55.98 (+0.38%)
BSX : 29.45 (-0.24%)
JNJ : 141.73 (+0.75%)
MRK : 63.89 (+0.60%)
BSGM : 1.5900 (+9.72%)
Earnings Review and Free Research Report: Johnson & Johnson EPS increased 13.0%; Revenue Advanced 10.3%

LONDON, UK / ACCESSWIRE / October 19, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Johnson & Johnson (NYSE: JNJ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=JNJ,...

JNJ : 141.73 (+0.75%)
Healthcare ETFs in Focus on Johnson & Johnson Q3 Earnings

Johnson & Johnson reports Q3 results with both revenues and EPS beating estimates.

XLV : 83.66 (+0.46%)
VHT : 155.36 (+0.35%)
JNJ : 141.73 (+0.75%)
IYH : 175.92 (+0.46%)
PFE : 36.32 (+1.37%)
UNH : 204.30 (-0.45%)
Arcturus Therapeutics Announces Strategic Collaboration with Johnson & Johnson Innovation to Discover and Develop RNA Medicines

Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it has entered into a research collaboration and worldwide license agreement with Janssen Pharmaceuticals, Inc. (Janssen),...

ADHD : 1.56 (+22.83%)
JNJ : 141.73 (+0.75%)
Johnson & Johnson Announces Quarterly Dividend for Fourth Quarter 2017

Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared a cash dividend for the fourth quarter of 2017 of $0.84 per share on the company's common stock. The dividend is...

JNJ : 141.73 (+0.75%)
Johnson & Johnson Medical GmbH to Acquire Surgical Process Institute

Johnson & Johnson Medical GmbH today announced a definitive agreement to acquire German software company, Surgical Process Institute (SPI), a leading specialist for the standardization and digitalization...

JNJ : 141.73 (+0.75%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More

Business Summary

Johnson & Johnson is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. Its Consumer segment offers products for use in the baby care, skin...

See More

Support & Resistance

2nd Resistance Point 142.29
1st Resistance Point 141.48
Last Price 141.72
1st Support Level 139.97
2nd Support Level 139.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart